OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
9
Results
Show all
Save search
Copy query
Show results for
Unknown
(9)
Publication Date
Release Date
2022
(3)
2023
(2)
2021
(2)
2025
(1)
2017
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Predicting Outcome and Therapy Response in mCRC Patients Using an Indirect Method for CTCs Detection by a Multigene Expression Panel: A Multicentric Prospective Validation Study.
Not available
S-EPMC5486087
|
biostudies-literature
Cite
Supramolecular fibrillation of peptide amphiphiles induces environmental responses in aqueous droplets.
Not available
S-EPMC8571317
|
biostudies-literature
Cite
Clinical significance of baseline Pan-Immune-Inflammation Value and its dynamics in metastatic colorectal cancer patients under first-line chemotherapy.
Not available
S-EPMC9046216
|
biostudies-literature
Cite
Unsupervised clustering based coronary artery segmentation.
Not available
S-EPMC11887207
|
biostudies-literature
Cite
Self-assembly of cyclic peptide monolayers by hydrophobic supramolecular hinges.
Not available
S-EPMC10717465
|
biostudies-literature
Cite
Noninvasive early detection of colorectal cancer by hypermethylation of the LINC00473 promoter in plasma cell-free DNA.
Not available
S-EPMC9271259
|
biostudies-literature
Cite
Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen.
Not available
S-EPMC9165891
|
biostudies-literature
Cite
Non-pharmaceutical interventions to combat COVID-19 in the Americas described through daily sub-national data.
Not available
S-EPMC10590388
|
biostudies-literature
Cite
A partisan pandemic: state government public health policies to combat COVID-19 in Brazil.
Not available
S-EPMC8182751
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets